Edison Pharmaceuticals adds to its rare mitochondrial disease portfolio
This article was originally published in Scrip
Executive Summary
Edison Pharmaceuticals, a privately held company that develops treatments for children with rare mitochondrial diseases, has licensed CNTO-530 from Centocor. The candidate is a clinical-stage compound, which is being evaluated in rare mitochondrial and other neglected diseases. The terms of the deal were not disclosed.